title: [Bowel obstruction-induced cholinergic crisis with progressive respiratory failure following distigmine bromide treatment].
abstract: A 54-year-old female experienced rapid respiratory failure while being transported in an ambulance to our emergency department for evaluation and management of constipation and abdominal pain. The patient was on treatment with distigmine bromide for postoperative urination disorder and magnesium oxide for constipation. Increased salivary secretions, diminished respiratory excursion, type 2 respiratory failure (PaCO2 : 65 mmHg), low serum cholinesterase, and hypermagnesemia were detected. Imaging studies revealed that the patient had bilateral aspiration pneumonia, fecal impaction in the rectum, and a distended colon causing ileus. The patient was mechanically ventilated and was weaned off the ventilator on day 3. Therapeutic drug monitoring after discharge revealed that the serum level of distigmine bromide on admission was markedly elevated (377.8 ng/mL vs. the normal therapeutic level of 5-10 ng/mL). Distigmine bromide induced a cholinergic crisis with a resultant increase in airway secretions and respiratory failure. In this particular case, orally administered distigmine bromide was excessively absorbed because of prolonged intestinal transit time secondary to fecal impaction and sluggish bowel movement; this caused a cholinergic crisis and hypermagnesemia contributing to respiratory failure. Clinicians should be aware that bowel obstruction in a patient treated with distigmine bromide can increase the risk of a cholinergic crisis.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sekiguchi
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sato
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirose
mesh_terms: D000284:Administration, Oral; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D002802:Cholinesterases / Q000097:blood*; D005260:Female; D006801:Humans; D045823:Ileus / Q000150:complications*; D007408:Intestinal Absorption; D008277:Magnesium Oxide / Q000009:adverse effects / Q000097:blood / Q000378:metabolism; D008875:Middle Aged; D011726:Pyridinium Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism; D012131:Respiratory Insufficiency / Q000209:etiology*
chemical_list: D002800:Cholinesterase Inhibitors; D011726:Pyridinium Compounds; D008277:Magnesium Oxide; D002802:Cholinesterases; C084645:distigmine